Intermittent β-adrenergic blockade downregulates the gene expression of β-myosin heavy chain in the mouse heart

Expression of the β-myosin heavy chain (β-MHC), a major component of the cardiac contractile apparatus, is tightly regulated as even modest increases can be detrimental to heart under stress. In healthy hearts, continuous inhibition of β-adrenergic tone upregulates β-MHC expression. However, it is u...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:European journal of pharmacology 2020-09, Vol.882, p.173287-173287, Article 173287
Hauptverfasser: Maccari, Sonia, Pace, Valentina, Barbagallo, Federica, Stati, Tonino, Ambrosio, Caterina, Grò, Maria Cristina, Molinari, Paola, Vezzi, Vanessa, Catalano, Liviana, Matarrese, Paola, Patrizio, Mario, Rizzi, Roberto, Marano, Giuseppe
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page 173287
container_issue
container_start_page 173287
container_title European journal of pharmacology
container_volume 882
creator Maccari, Sonia
Pace, Valentina
Barbagallo, Federica
Stati, Tonino
Ambrosio, Caterina
Grò, Maria Cristina
Molinari, Paola
Vezzi, Vanessa
Catalano, Liviana
Matarrese, Paola
Patrizio, Mario
Rizzi, Roberto
Marano, Giuseppe
description Expression of the β-myosin heavy chain (β-MHC), a major component of the cardiac contractile apparatus, is tightly regulated as even modest increases can be detrimental to heart under stress. In healthy hearts, continuous inhibition of β-adrenergic tone upregulates β-MHC expression. However, it is unknown whether the duration of the β-adrenergic inhibition and β-MHC expression are related. Here, we evaluated the effects of intermittent β-blockade on cardiac β-MHC expression. To this end, the β-blocker propranolol, at the dose of 15mg/kg, was administered once a day in mice for 14 days. This dosing schedule caused daily drug-free periods of at least 6 h as evidenced by propranolol plasma concentrations and cardiac β-adrenergic responsiveness. Under these conditions, β-MHC expression decreased by about 75% compared to controls. This effect was abolished in mice lacking β1- but not β2-adrenergic receptors (β-AR) indicating that β-MHC expression is regulated in a β1-AR-dependent manner. In β1-AR knockout mice, the baseline β-MHC expression was fourfold higher than in wild-type mice. Also, we evaluated the impact of intermittent β-blockade on β-MHC expression in mice with systolic dysfunction, in which an increased β-MHC expression occurs. At 3 weeks after myocardial infarction, mice showed systolic dysfunction and upregulation of β-MHC expression. Intermittent β-blockade decreased β-MHC expression while attenuating cardiac dysfunction. In vitro studies showed that propranolol does not affect β-MHC expression on its own but antagonizes catecholamine effects on β-MHC expression. In conclusion, a direct relationship occurs between the duration of the β-adrenergic inhibition and β-MHC expression through the β1-AR.
doi_str_mv 10.1016/j.ejphar.2020.173287
format Article
fullrecord <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_2418131438</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S0014299920303794</els_id><sourcerecordid>2418131438</sourcerecordid><originalsourceid>FETCH-LOGICAL-c432t-f670d0b06aba5a372ddac3e069f4a35e16f7ae400c0894946403a65dc89bc4a93</originalsourceid><addsrcrecordid>eNp9kEtuFDEQhi0EIkPgBgh5yaaH8qMf3iChCJJIkdjA2nLb1TMeutsT25Mw1-IgnAm3OrBEsmTL_n5X1UfIWwZbBqz5cNji4bg3ccuBl6tW8K59Rjasa1UFLePPyQaAyYorpS7Iq5QOAFArXr8kF4LXXc3qdkPub-eMcfI545zp71-VcRFnjDtvaT8G-8M4pC48zhF3p9FkTDTvke4KQ_HnMWJKPsw0DEt2OofkZ7pH83Cmdm_KuayFn8Ip4fIQ82vyYjBjwjdP-yX5_uXzt6ub6u7r9e3Vp7vKSsFzNTQtOOihMb2pjWi5c8YKhEYN0ogaWTO0BiWAhU5JJRsJwjS1s53qrTRKXJL367_HGO5PmLKefLI4jmbG0o3mknVMMCm6gsoVtTGkFHHQx-gnE8-agV5k64NeZetFtl5ll9i7pwqnfkL3L_TXbgE-rgCWOR88Rp2sx9mi8xFt1i74_1f4A1nLlT8</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2418131438</pqid></control><display><type>article</type><title>Intermittent β-adrenergic blockade downregulates the gene expression of β-myosin heavy chain in the mouse heart</title><source>MEDLINE</source><source>Access via ScienceDirect (Elsevier)</source><creator>Maccari, Sonia ; Pace, Valentina ; Barbagallo, Federica ; Stati, Tonino ; Ambrosio, Caterina ; Grò, Maria Cristina ; Molinari, Paola ; Vezzi, Vanessa ; Catalano, Liviana ; Matarrese, Paola ; Patrizio, Mario ; Rizzi, Roberto ; Marano, Giuseppe</creator><creatorcontrib>Maccari, Sonia ; Pace, Valentina ; Barbagallo, Federica ; Stati, Tonino ; Ambrosio, Caterina ; Grò, Maria Cristina ; Molinari, Paola ; Vezzi, Vanessa ; Catalano, Liviana ; Matarrese, Paola ; Patrizio, Mario ; Rizzi, Roberto ; Marano, Giuseppe</creatorcontrib><description>Expression of the β-myosin heavy chain (β-MHC), a major component of the cardiac contractile apparatus, is tightly regulated as even modest increases can be detrimental to heart under stress. In healthy hearts, continuous inhibition of β-adrenergic tone upregulates β-MHC expression. However, it is unknown whether the duration of the β-adrenergic inhibition and β-MHC expression are related. Here, we evaluated the effects of intermittent β-blockade on cardiac β-MHC expression. To this end, the β-blocker propranolol, at the dose of 15mg/kg, was administered once a day in mice for 14 days. This dosing schedule caused daily drug-free periods of at least 6 h as evidenced by propranolol plasma concentrations and cardiac β-adrenergic responsiveness. Under these conditions, β-MHC expression decreased by about 75% compared to controls. This effect was abolished in mice lacking β1- but not β2-adrenergic receptors (β-AR) indicating that β-MHC expression is regulated in a β1-AR-dependent manner. In β1-AR knockout mice, the baseline β-MHC expression was fourfold higher than in wild-type mice. Also, we evaluated the impact of intermittent β-blockade on β-MHC expression in mice with systolic dysfunction, in which an increased β-MHC expression occurs. At 3 weeks after myocardial infarction, mice showed systolic dysfunction and upregulation of β-MHC expression. Intermittent β-blockade decreased β-MHC expression while attenuating cardiac dysfunction. In vitro studies showed that propranolol does not affect β-MHC expression on its own but antagonizes catecholamine effects on β-MHC expression. In conclusion, a direct relationship occurs between the duration of the β-adrenergic inhibition and β-MHC expression through the β1-AR.</description><identifier>ISSN: 0014-2999</identifier><identifier>EISSN: 1879-0712</identifier><identifier>DOI: 10.1016/j.ejphar.2020.173287</identifier><identifier>PMID: 32585157</identifier><language>eng</language><publisher>Netherlands: Elsevier B.V</publisher><subject>Adrenergic beta-Agonists - pharmacology ; Adrenergic beta-Antagonists - blood ; Adrenergic beta-Antagonists - pharmacokinetics ; Adrenergic beta-Antagonists - pharmacology ; Adrenergic beta-Antagonists - therapeutic use ; Animals ; Down-Regulation - drug effects ; Female ; Gene expression ; Isoproterenol - pharmacology ; Male ; Mice, Inbred C57BL ; Mice, Knockout ; Myocardial Infarction - drug therapy ; Myocardial Infarction - genetics ; Myocardial Infarction - pathology ; Myocardium - metabolism ; Myosin Heavy Chains - genetics ; Propranolol - blood ; Propranolol - pharmacokinetics ; Propranolol - pharmacology ; Propranolol - therapeutic use ; Receptors, Adrenergic, beta - genetics ; Ventricular Myosins - genetics ; β-adrenergic receptors ; β-blockers ; β-myosin heavy chain</subject><ispartof>European journal of pharmacology, 2020-09, Vol.882, p.173287-173287, Article 173287</ispartof><rights>2020 Elsevier B.V.</rights><rights>Copyright © 2020 Elsevier B.V. All rights reserved.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c432t-f670d0b06aba5a372ddac3e069f4a35e16f7ae400c0894946403a65dc89bc4a93</citedby><cites>FETCH-LOGICAL-c432t-f670d0b06aba5a372ddac3e069f4a35e16f7ae400c0894946403a65dc89bc4a93</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://dx.doi.org/10.1016/j.ejphar.2020.173287$$EHTML$$P50$$Gelsevier$$H</linktohtml><link.rule.ids>314,780,784,3550,27924,27925,45995</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/32585157$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Maccari, Sonia</creatorcontrib><creatorcontrib>Pace, Valentina</creatorcontrib><creatorcontrib>Barbagallo, Federica</creatorcontrib><creatorcontrib>Stati, Tonino</creatorcontrib><creatorcontrib>Ambrosio, Caterina</creatorcontrib><creatorcontrib>Grò, Maria Cristina</creatorcontrib><creatorcontrib>Molinari, Paola</creatorcontrib><creatorcontrib>Vezzi, Vanessa</creatorcontrib><creatorcontrib>Catalano, Liviana</creatorcontrib><creatorcontrib>Matarrese, Paola</creatorcontrib><creatorcontrib>Patrizio, Mario</creatorcontrib><creatorcontrib>Rizzi, Roberto</creatorcontrib><creatorcontrib>Marano, Giuseppe</creatorcontrib><title>Intermittent β-adrenergic blockade downregulates the gene expression of β-myosin heavy chain in the mouse heart</title><title>European journal of pharmacology</title><addtitle>Eur J Pharmacol</addtitle><description>Expression of the β-myosin heavy chain (β-MHC), a major component of the cardiac contractile apparatus, is tightly regulated as even modest increases can be detrimental to heart under stress. In healthy hearts, continuous inhibition of β-adrenergic tone upregulates β-MHC expression. However, it is unknown whether the duration of the β-adrenergic inhibition and β-MHC expression are related. Here, we evaluated the effects of intermittent β-blockade on cardiac β-MHC expression. To this end, the β-blocker propranolol, at the dose of 15mg/kg, was administered once a day in mice for 14 days. This dosing schedule caused daily drug-free periods of at least 6 h as evidenced by propranolol plasma concentrations and cardiac β-adrenergic responsiveness. Under these conditions, β-MHC expression decreased by about 75% compared to controls. This effect was abolished in mice lacking β1- but not β2-adrenergic receptors (β-AR) indicating that β-MHC expression is regulated in a β1-AR-dependent manner. In β1-AR knockout mice, the baseline β-MHC expression was fourfold higher than in wild-type mice. Also, we evaluated the impact of intermittent β-blockade on β-MHC expression in mice with systolic dysfunction, in which an increased β-MHC expression occurs. At 3 weeks after myocardial infarction, mice showed systolic dysfunction and upregulation of β-MHC expression. Intermittent β-blockade decreased β-MHC expression while attenuating cardiac dysfunction. In vitro studies showed that propranolol does not affect β-MHC expression on its own but antagonizes catecholamine effects on β-MHC expression. In conclusion, a direct relationship occurs between the duration of the β-adrenergic inhibition and β-MHC expression through the β1-AR.</description><subject>Adrenergic beta-Agonists - pharmacology</subject><subject>Adrenergic beta-Antagonists - blood</subject><subject>Adrenergic beta-Antagonists - pharmacokinetics</subject><subject>Adrenergic beta-Antagonists - pharmacology</subject><subject>Adrenergic beta-Antagonists - therapeutic use</subject><subject>Animals</subject><subject>Down-Regulation - drug effects</subject><subject>Female</subject><subject>Gene expression</subject><subject>Isoproterenol - pharmacology</subject><subject>Male</subject><subject>Mice, Inbred C57BL</subject><subject>Mice, Knockout</subject><subject>Myocardial Infarction - drug therapy</subject><subject>Myocardial Infarction - genetics</subject><subject>Myocardial Infarction - pathology</subject><subject>Myocardium - metabolism</subject><subject>Myosin Heavy Chains - genetics</subject><subject>Propranolol - blood</subject><subject>Propranolol - pharmacokinetics</subject><subject>Propranolol - pharmacology</subject><subject>Propranolol - therapeutic use</subject><subject>Receptors, Adrenergic, beta - genetics</subject><subject>Ventricular Myosins - genetics</subject><subject>β-adrenergic receptors</subject><subject>β-blockers</subject><subject>β-myosin heavy chain</subject><issn>0014-2999</issn><issn>1879-0712</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2020</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNp9kEtuFDEQhi0EIkPgBgh5yaaH8qMf3iChCJJIkdjA2nLb1TMeutsT25Mw1-IgnAm3OrBEsmTL_n5X1UfIWwZbBqz5cNji4bg3ccuBl6tW8K59Rjasa1UFLePPyQaAyYorpS7Iq5QOAFArXr8kF4LXXc3qdkPub-eMcfI545zp71-VcRFnjDtvaT8G-8M4pC48zhF3p9FkTDTvke4KQ_HnMWJKPsw0DEt2OofkZ7pH83Cmdm_KuayFn8Ip4fIQ82vyYjBjwjdP-yX5_uXzt6ub6u7r9e3Vp7vKSsFzNTQtOOihMb2pjWi5c8YKhEYN0ogaWTO0BiWAhU5JJRsJwjS1s53qrTRKXJL367_HGO5PmLKefLI4jmbG0o3mknVMMCm6gsoVtTGkFHHQx-gnE8-agV5k64NeZetFtl5ll9i7pwqnfkL3L_TXbgE-rgCWOR88Rp2sx9mi8xFt1i74_1f4A1nLlT8</recordid><startdate>20200905</startdate><enddate>20200905</enddate><creator>Maccari, Sonia</creator><creator>Pace, Valentina</creator><creator>Barbagallo, Federica</creator><creator>Stati, Tonino</creator><creator>Ambrosio, Caterina</creator><creator>Grò, Maria Cristina</creator><creator>Molinari, Paola</creator><creator>Vezzi, Vanessa</creator><creator>Catalano, Liviana</creator><creator>Matarrese, Paola</creator><creator>Patrizio, Mario</creator><creator>Rizzi, Roberto</creator><creator>Marano, Giuseppe</creator><general>Elsevier B.V</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>20200905</creationdate><title>Intermittent β-adrenergic blockade downregulates the gene expression of β-myosin heavy chain in the mouse heart</title><author>Maccari, Sonia ; Pace, Valentina ; Barbagallo, Federica ; Stati, Tonino ; Ambrosio, Caterina ; Grò, Maria Cristina ; Molinari, Paola ; Vezzi, Vanessa ; Catalano, Liviana ; Matarrese, Paola ; Patrizio, Mario ; Rizzi, Roberto ; Marano, Giuseppe</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c432t-f670d0b06aba5a372ddac3e069f4a35e16f7ae400c0894946403a65dc89bc4a93</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2020</creationdate><topic>Adrenergic beta-Agonists - pharmacology</topic><topic>Adrenergic beta-Antagonists - blood</topic><topic>Adrenergic beta-Antagonists - pharmacokinetics</topic><topic>Adrenergic beta-Antagonists - pharmacology</topic><topic>Adrenergic beta-Antagonists - therapeutic use</topic><topic>Animals</topic><topic>Down-Regulation - drug effects</topic><topic>Female</topic><topic>Gene expression</topic><topic>Isoproterenol - pharmacology</topic><topic>Male</topic><topic>Mice, Inbred C57BL</topic><topic>Mice, Knockout</topic><topic>Myocardial Infarction - drug therapy</topic><topic>Myocardial Infarction - genetics</topic><topic>Myocardial Infarction - pathology</topic><topic>Myocardium - metabolism</topic><topic>Myosin Heavy Chains - genetics</topic><topic>Propranolol - blood</topic><topic>Propranolol - pharmacokinetics</topic><topic>Propranolol - pharmacology</topic><topic>Propranolol - therapeutic use</topic><topic>Receptors, Adrenergic, beta - genetics</topic><topic>Ventricular Myosins - genetics</topic><topic>β-adrenergic receptors</topic><topic>β-blockers</topic><topic>β-myosin heavy chain</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Maccari, Sonia</creatorcontrib><creatorcontrib>Pace, Valentina</creatorcontrib><creatorcontrib>Barbagallo, Federica</creatorcontrib><creatorcontrib>Stati, Tonino</creatorcontrib><creatorcontrib>Ambrosio, Caterina</creatorcontrib><creatorcontrib>Grò, Maria Cristina</creatorcontrib><creatorcontrib>Molinari, Paola</creatorcontrib><creatorcontrib>Vezzi, Vanessa</creatorcontrib><creatorcontrib>Catalano, Liviana</creatorcontrib><creatorcontrib>Matarrese, Paola</creatorcontrib><creatorcontrib>Patrizio, Mario</creatorcontrib><creatorcontrib>Rizzi, Roberto</creatorcontrib><creatorcontrib>Marano, Giuseppe</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>European journal of pharmacology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Maccari, Sonia</au><au>Pace, Valentina</au><au>Barbagallo, Federica</au><au>Stati, Tonino</au><au>Ambrosio, Caterina</au><au>Grò, Maria Cristina</au><au>Molinari, Paola</au><au>Vezzi, Vanessa</au><au>Catalano, Liviana</au><au>Matarrese, Paola</au><au>Patrizio, Mario</au><au>Rizzi, Roberto</au><au>Marano, Giuseppe</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Intermittent β-adrenergic blockade downregulates the gene expression of β-myosin heavy chain in the mouse heart</atitle><jtitle>European journal of pharmacology</jtitle><addtitle>Eur J Pharmacol</addtitle><date>2020-09-05</date><risdate>2020</risdate><volume>882</volume><spage>173287</spage><epage>173287</epage><pages>173287-173287</pages><artnum>173287</artnum><issn>0014-2999</issn><eissn>1879-0712</eissn><abstract>Expression of the β-myosin heavy chain (β-MHC), a major component of the cardiac contractile apparatus, is tightly regulated as even modest increases can be detrimental to heart under stress. In healthy hearts, continuous inhibition of β-adrenergic tone upregulates β-MHC expression. However, it is unknown whether the duration of the β-adrenergic inhibition and β-MHC expression are related. Here, we evaluated the effects of intermittent β-blockade on cardiac β-MHC expression. To this end, the β-blocker propranolol, at the dose of 15mg/kg, was administered once a day in mice for 14 days. This dosing schedule caused daily drug-free periods of at least 6 h as evidenced by propranolol plasma concentrations and cardiac β-adrenergic responsiveness. Under these conditions, β-MHC expression decreased by about 75% compared to controls. This effect was abolished in mice lacking β1- but not β2-adrenergic receptors (β-AR) indicating that β-MHC expression is regulated in a β1-AR-dependent manner. In β1-AR knockout mice, the baseline β-MHC expression was fourfold higher than in wild-type mice. Also, we evaluated the impact of intermittent β-blockade on β-MHC expression in mice with systolic dysfunction, in which an increased β-MHC expression occurs. At 3 weeks after myocardial infarction, mice showed systolic dysfunction and upregulation of β-MHC expression. Intermittent β-blockade decreased β-MHC expression while attenuating cardiac dysfunction. In vitro studies showed that propranolol does not affect β-MHC expression on its own but antagonizes catecholamine effects on β-MHC expression. In conclusion, a direct relationship occurs between the duration of the β-adrenergic inhibition and β-MHC expression through the β1-AR.</abstract><cop>Netherlands</cop><pub>Elsevier B.V</pub><pmid>32585157</pmid><doi>10.1016/j.ejphar.2020.173287</doi><tpages>1</tpages></addata></record>
fulltext fulltext
identifier ISSN: 0014-2999
ispartof European journal of pharmacology, 2020-09, Vol.882, p.173287-173287, Article 173287
issn 0014-2999
1879-0712
language eng
recordid cdi_proquest_miscellaneous_2418131438
source MEDLINE; Access via ScienceDirect (Elsevier)
subjects Adrenergic beta-Agonists - pharmacology
Adrenergic beta-Antagonists - blood
Adrenergic beta-Antagonists - pharmacokinetics
Adrenergic beta-Antagonists - pharmacology
Adrenergic beta-Antagonists - therapeutic use
Animals
Down-Regulation - drug effects
Female
Gene expression
Isoproterenol - pharmacology
Male
Mice, Inbred C57BL
Mice, Knockout
Myocardial Infarction - drug therapy
Myocardial Infarction - genetics
Myocardial Infarction - pathology
Myocardium - metabolism
Myosin Heavy Chains - genetics
Propranolol - blood
Propranolol - pharmacokinetics
Propranolol - pharmacology
Propranolol - therapeutic use
Receptors, Adrenergic, beta - genetics
Ventricular Myosins - genetics
β-adrenergic receptors
β-blockers
β-myosin heavy chain
title Intermittent β-adrenergic blockade downregulates the gene expression of β-myosin heavy chain in the mouse heart
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-27T11%3A59%3A56IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Intermittent%20%CE%B2-adrenergic%20blockade%20downregulates%20the%20gene%20expression%20of%20%CE%B2-myosin%20heavy%20chain%20in%20the%20mouse%20heart&rft.jtitle=European%20journal%20of%20pharmacology&rft.au=Maccari,%20Sonia&rft.date=2020-09-05&rft.volume=882&rft.spage=173287&rft.epage=173287&rft.pages=173287-173287&rft.artnum=173287&rft.issn=0014-2999&rft.eissn=1879-0712&rft_id=info:doi/10.1016/j.ejphar.2020.173287&rft_dat=%3Cproquest_cross%3E2418131438%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2418131438&rft_id=info:pmid/32585157&rft_els_id=S0014299920303794&rfr_iscdi=true